FIELD: biotechnology.
SUBSTANCE: invention relates to an IL-2 conjugate containing an amino acid sequence having at least approximately 80% identity to SEQ ID NO: 3, where at least one amino acid residue in an amino acid position selected from K34, F41, K42, E61, P64, R37, T40, E67, Y44 and V68, relating to positions of amino acids in SEQ ID NO: 3, is replaced by the structure of formula (I), where the values of X, Y, Z are defined in the claims, and the method for production thereof. Also disclosed are pharmaceutical compositions containing one or more conjugates of IL-2.
EFFECT: conjugates of IL-2 are intended for treating cancer in a patient.
21 cl, 36 dwg, 19 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEUKIN 10 CONJUGATES AND APPLICATIONS THEREOF | 2020 |
|
RU2829811C1 |
| CYTOKINE CONJUGATES FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2787201C2 |
| HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE | 2019 |
|
RU2799437C2 |
| ESCHERICHIA COLI COMPOSITIONS AND METHODS BASED THEREON | 2021 |
|
RU2821929C1 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| RECOMBINANT pMHC MOLECULES OF CLASS II | 2017 |
|
RU2777115C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF EYE DISEASES | 2018 |
|
RU2782355C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
